Guardant360 CDx Test Gets ADLT Status from CMS
The Guardant360 CDx test is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers.
The Guardant360 CDx test is the first FDA-approved liquid biopsy for comprehensive tumor mutation profiling across all solid cancers.
The lead researcher says the results will have a positive effect on patient care because patients will know whether breast cancer VUS are benign or pathogenic.
The study suggests that such liquid biopsies could help personalize treatment for oligometastatic colorectal cancer.
The Hologic Genius Digital Diagnostics System is expected to derive even more actionable insights from cytology slides for cytotechnologists and pathologists with Google Cloud.
Read MoreStudy to focus on using saliva in the analysis of cell-free circulating tumor DNA to accurately and noninvasively detect non-small cell lung cancer.
Read MoreNew research has demonstrated that a simple, cheap test can help identify who is at risk of developing colorectal cancer, aiding early diagnosis and potentially saving lives.
Read MoreMultiMMR, an alternative to complex, multistep testing workflows, was able to identify causes of MMR deficiency often missed by current clinical tests.
Read MoreCaris Life Sciences’ MI GPSai was validated on over 19,500 cases, predicting tumor types with an accuracy of over 94% on 93% of cases while deliberating among 21 possible categories of cancer.
Read MoreNew survey results show strong support for this standby of cervical cancer screening.
Read MoreThrough this agreement, Biodesix will develop a companion diagnostic to select patients for enrollment in HiberCell’s future registrational clinical trials.
Read MoreGrowth of RNA sequencing allows physicians and researchers to analyze a patient’s full genetic profile.
Read MoreThe company’s noninvasive liquid biopsy test for ovarian cancer will have final data from its initial clinical trial in the first half of 2021, and InterVenn’s on-site laboratory has received CLIA certification to make its tests available to the medical community.
Read MoreThe strategic partnership between Myriad and Illumina consists of a time-limited exclusive agreement for Illumina to provide a kit-based version of the myChoice CDx test for international markets.
Read MoreIllumina has established oncology partnerships with Bristol Myers Squibb, Kura Oncology, Myriad Genetics, and Merck to expand the reach of TruSight Oncology.
Read MoreuPath HER2 (4B5) image analysis and uPath Dual ISH image analysis for breast cancer use AI to aid pathologists’ decision-making.
Read MoreWith Concentriq, LabPON gains added flexibility to scale its routine digital pathology operations as the total number of worldwide cancer cases continues to rise.
Read MoreBiotheranostics is a privately held, commercial-stage company that provides molecular diagnostic tests for breast and metastatic cancers.
Read MoreData from RxPONDER trial successfully defined the benefit of chemotherapy in early-stage, node-positive breast cancer patients with Oncotype DX Breast Recurrence Score results of 0 to 25.
Read More